Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
暂无分享,去创建一个
Suzanne F. Jones | M. Ellis | A. Stead | K. Blackwell | B. Overmoyer | H. Hurwitz | P. Marcom | H. Burris | E. Dees | N. Spector | A. Dowlati | Deborah A. Smith | K. Koch | B. O'Neil | H. Burris | Jennifer Harris | S. Mangum | Jennifer L. Harris